mRNAの治療薬と世界市場

Report Scope

The report analyzes the global market for mRNA therapeutics. It includes global revenue ($ millions) for the base year of 2024, estimated data for 2025 and projected compound annual growth rates (CAGRs) through 2030. The report examines the different types of mRNA and their applications for therapeutic use. It also focuses on mRNA patents and clinical trials and examines the trends affecting the market during the forecast period. The report profiles the leading companies and their strategic alliances and partnerships. The report segments the global market into North America, Europe, Asia-Pacific (APAC) and the Rest of the World (RoW).

Report Includes
– 19 data tables and 71 additional tables
– An overview and analysis of the global markets for messenger RNA (mRNA)-based therapeutics
– Analyses of the global market trends, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
– Estimates of the size and revenue prospects for the global mRNA market, along with a market share analysis by disease type, indication, and region
– Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations and the impacts of macroeconomic variables
– Insights derived from Porter’s Five Forces model, global supply chain and PESTLE analyses
– Patent analysis, featuring key granted and published patents
– Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings and consumer attitudes
– Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
– Profiles of the leading companies, including Moderna Inc., Pfizer Inc., BioNTech SE, Merck & Co., and Sanofi

Table of Contents

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Market Growth Factors
Emerging Technologies
COVID mRNA Vaccines
Regional Analysis
Conclusion
Chapter 2 Market Overview
Technology Background
Evolution of RNA Therapeutics
DNA Therapeutics vs. RNA Therapeutics
RNA Therapeutics
mRNA as Therapeutics
Regulatory Agency-Approved mRNA Vaccines
Porter’s Five Forces Analysis
Potential for New Entrants
Bargaining Power of Suppliers
Bargaining Power of Buyers
Threat of Substitute Products or Services
Industry Competition
Impact of U.S. Tariffs on the mRNA Therapeutics Market
Conclusion
Chapter 3 Market Dynamics
Overview
Market Drivers
Rising Numbers of Pandemics and Epidemics
Awareness of the Need for Vaccinations
Investments in mRNA Therapeutics Research
Market Restraints
Limitations of mRNA Vaccines
Production and Logistical Hurdles
Market Opportunities
Personalized Cancer Vaccines
Potential of mRNA Drugs to Treat Various Diseases
Chapter 4 Regulatory Landscape
Regulatory Scenario
Overview of Regulatory Bodies
Guidelines and Standards for mRNA Vaccines
Preclinical and Clinical Evaluation
Manufacturing and Post-Marketing Surveillance
Continual Monitoring and Risk Management
Chapter 5 Pipeline and Clinical Trial Analysis
Takeaways
mRNA Vaccines
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Breakdown by Disease Type
Takeaways
COVID mRNA Vaccines
Non-COVID mRNA Vaccines and Therapeutics
Market Breakdown by Indication
Cancer
Infectious Diseases
Rare Diseases
Others
Geographic Breakdown
Market Breakdown, by Region
Takeaways
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Emerging Technologies and Developments
Emerging Technologies in mRNA Therapeutics
Nanoparticles
Modified mRNA
Automated mRNA Synthesis Kits
Bio Platforms
Artificial Intelligence
AI Developments at mRNA Therapeutics Companies
Chapter 8 Patent Analysis
Takeaways
mRNA Publications
List of Patents
Chapter 9 Sustainability in the mRNA Therapeutics Industry: An ESG Perspective
Sustainability in the mRNA Therapeutics Industry
ESG Risk Ratings
ESG Performance Analysis
Environmental Performance
Social Performance
Governance Performance
Concluding Remarks from BCC Research
Chapter 10 Competitive Intelligence
Takeaways
Leading Companies in the mRNA Therapeutics Market, 2024
Strategic Analysis
Collaborations and Partnerships
Regulatory Approvals
Clinical Trials Data
Funding and Grants
Chapter 11 Appendix
Methodology
Abbreviations
Sources
Company Profiles
ARCTURUS THERAPEUTICS INC.
ASTRAZENECA
BIOCINA
BIONTECH SE
CUREVAC SE
ETHRIS GMBH
GENNOVA BIOPHARMACEUTICALS LTD.
GSK PLC.
IMMORNA (HANGZHOU) BIOTECHNOLOGY CO. LTD.
MERCK & CO. INC.
MODERNA INC.
NUTCRACKER THERAPEUTICS INC.
PFIZER INC.
PROVIDENCE THERAPEUTICS
SANOFI
STRAND THERAPEUTICS INC.

List of Tables

List of Tables
Summary Table : Global Market for mRNA Therapeutics, by Disease, Through 2030
Table 1 : Evolution of RNA Therapeutics
Table 2 : Approved mRNA Vaccines, 2025
Table 3 : Pandemics of the 21st Century
Table 4 : Status of Clinical Trials for mRNA-based Drugs, 2025
Table 5 : Clinical Trials for mRNA Vaccines, 2025
Table 6 : Global Market for mRNA Therapeutics, by Disease Type, Through 2030
Table 7 : Properties of the BNT162b2 Vaccine
Table 8 : Properties of the mRNA-1273 Vaccine
Table 9 : Properties of the CVnCoV Vaccine
Table 10 : Global Market for COVID mRNA Therapeutics, by Region, Through 2030
Table 11 : Global Market for Non-COVID mRNA Vaccines and Therapeutics, by Region, Through 2030
Table 12 : Global Cancer-Related Deaths, by Cancer Type, Through 2030
Table 13 : Global Market for mRNA Therapeutics, by Region, Through 2030
Table 14 : North American Market for mRNA Therapeutics, by Disease Type, Through 2030
Table 15 : European Market for mRNA Therapeutics, by Disease Type, Through 2030
Table 16 : Asia-Pacific Market for mRNA Therapeutics, by Disease Type, Through 2030
Table 17 : RoW Market for mRNA Therapeutics, by Disease Type, Through 2030
Table 18 : Organizations with the Most Published mRNA Patents
Table 19 : Patents for mRNA Therapeutics, 2025
Table 20 : Patents Related to mRNA Vaccines for Infectious Diseases, 2025
Table 21 : Patents Related to mRNA Vaccines for Cancer Treatment, 2025
Table 22 : Patents Focused on mRNA Delivery and Modification
Table 23 : Focus Areas in ESG Metrics
Table 24 : ESG Rankings for Major mRNA Therapeutics Companies, 2025*
Table 25 : ESG: Environmental Overview
Table 26 : ESG: Social Factors Overview
Table 27 : ESG: Governance Overview
Table 28 : Collaborations and Partnerships in the mRNA Therapeutics Market, 2023–2025
Table 29 : Regulatory Approvals in the mRNA Therapeutics Industry, 2023–2025
Table 30 : Clinical Trial Data in the mRNA Therapeutics Market, 2022–2025
Table 31 : Funding and Grants in the mRNA Therapeutics Market, 2023–2025
Table 32 : Abbreviations Used in this Report
Table 33 : Arcturus Therapeutics Inc.: Company Snapshot
Table 34 : Arcturus Therapeutics Inc.: Financial Performance, FY 2023 and 2024
Table 35 : Arcturus Therapeutics Inc.: Product Pipeline
Table 36 : Arcturus Therapeutics Inc.: News/Key Developments, 2024-2025
Table 37 : AstraZeneca: Company Snapshot
Table 38 : AstraZeneca: Financial Performance, FY 2023 and 2024
Table 39 : AstraZeneca: Product Pipeline
Table 40 : AstraZeneca: News/Key Developments, 2025
Table 41 : BioCina: Company Snapshot
Table 42 : BioCina: Product Portfolio
Table 43 : BioCina: News/Key Developments, 2023-2025
Table 44 : BioNTech SE: Company Snapshot
Table 45 : BioNTech SE: Financial Performance, FY 2023 and 2024
Table 46 : BioNTech SE: Product Pipeline
Table 47 : BioNTech SE: News/Key Developments, 2023-2024
Table 48 : CureVac SE: Company Snapshot
Table 49 : CureVac SE: Financial Performance, FY 2023 and 2024
Table 50 : CureVac SE: Product Pipeline
Table 51 : CureVac SE: News/Key Developments, 2024-2025
Table 52 : Ethris GmbH: Company Snapshot
Table 53 : Ethris GmbH: Product Pipeline
Table 54 : Ethris GmbH: News/Key Developments, 2023-2025
Table 55 : Gennova Biopharmaceuticals Ltd.: Company Snapshot
Table 56 : Gennova Biopharmaceuticals Ltd.: Product Portfolio
Table 57 : Gennova Biopharmaceuticals Ltd.: News/Key Developments, 2023
Table 58 : GSK PLC: Company Snapshot
Table 59 : GSK PLC: Financial Performance, FY 2023 and 2024
Table 60 : GSK PLC: Product Pipeline
Table 61 : GSK PLC: News/Key Developments, 2024
Table 62 : Immorna Biotechnology Co. Ltd.: Company Snapshot
Table 63 : Immorna Biotechnology Co. Ltd.: Product Pipeline
Table 64 : Immorna Biotechnology Co. Ltd: News/Key Developments, 2024-2025
Table 65 : Merck & Co. Inc.: Company Snapshot
Table 66 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
Table 67 : Merck & Co. Inc.: Product Pipeline
Table 68 : Merck & Co. Inc.: News/Key Developments, 2023
Table 69 : Moderna Inc.: Company Snapshot
Table 70 : Moderna Inc.: Financial Performance, FY 2023 and 2024
Table 71 : Moderna Inc.: Product Pipeline
Table 72 : Moderna Inc.: News/Key Developments, 2024-2025
Table 73 : Nutcracker Therapeutics Inc.: Company Snapshot
Table 74 : Nutcracker Therapeutics Inc.: Product Portfolio
Table 75 : Nutcracker Therapeutics Inc.: News/Key Developments, 2024-2025
Table 76 : Pfizer Inc.: Company Snapshot
Table 77 : Pfizer Inc.: Financial Performance, FY 2023 and 2024
Table 78 : Pfizer Inc.: Product Portfolio
Table 79 : Pfizer Inc.: News/Key Developments, 2024
Table 80 : Providence Therapeutics: Company Snapshot
Table 81 : Providence Therapeutics: Product Pipeline
Table 82 : Providence Therapeutics: News/Key Developments, 2022–2024
Table 83 : Sanofi: Company Snapshot
Table 84 : Sanofi: Financial Performance, FY 2023 and 2024
Table 85 : Sanofi: Product Pipeline
Table 86 : Sanofi: News/Key Developments, 2024-2025
Table 87 : Strand Therapeutics Inc.: Company Snapshot
Table 88 : Strand Therapeutics Inc.: Product Pipeline
Table 89 : Strand Therapeutics Inc.: News/Key Developments, 2024–2025

List of Figures

List of Figures
Summary Figure : Global Market Shares of mRNA Therapeutics, by Disease, 2024
Figure 1 : Porter’s Five Forces Analysis
Figure 2 : Snapshot of Market Dynamics
Figure 3 : Factors Responsible for the Rising Number of Pandemics
Figure 4 : Clinical Trials for mRNA Vaccines, by Disease Indication, 2023–2025
Figure 5 : mRNA Vaccine Candidates in Clinical Trials, by Phase, 2023–2025
Figure 6 : mRNA Vaccine Candidates in Clinical Trials, by Study Type, 2023–2025
Figure 7 : mRNA Vaccine Candidates in Clinical Trials, by Funding Source, 2023–2025
Figure 8 : Global Market Shares of mRNA Therapeutics, by Disease Type, 2024
Figure 9 : Global Cancer-Related Deaths, by Cancer Type, 2000–2030
Figure 10 : Global Market Shares of mRNA Therapeutics, by Region, 2024
Figure 11 : Emerging Technologies in mRNA Therapeutics
Figure 12 : Patents on mRNA Therapeutics, 2010–2022
Figure 13 : Patent Shares on mRNA Therapeutics, by Patent Classification, 2010–2021
Figure 14 : Published mRNA-based Patents, 2019–2022
Figure 15 : How a Strong ESG Proposition Can Benefit Businesses
Figure 16 : Moderna’s mRNA Therapeutics Product Pipeline, by Clinical Phase, 2025
Figure 17 : BioNTech’s mRNA Therapeutics Product Pipeline, by Clinical Phase, 2025
Figure 18 : Arcturus Therapeutics Inc: Revenue Shares, by Business Unit, FY 2024
Figure 19 : AstraZeneca: Revenue Shares, by Business Unit, FY 2024
Figure 20 : AstraZeneca: Revenue Shares, by Region/Country, FY 2024
Figure 21 : BioNTech SE: Revenue Shares, by Region/Country, FY 2024
Figure 22 : GSK PLC: Revenue Shares, by Business Unit, FY 2024
Figure 23 : GSK PLC: Revenue Shares, by Region/Country, FY 2024
Figure 24 : Merck & Co. Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 25 : Merck & Co. Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 26 : Moderna Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 27 : Pfizer Inc.: Revenue Shares, by Business Unit, FY 2024
Figure 28 : Pfizer Inc.: Revenue Shares, by Country/Region, FY 2024
Figure 29 : Sanofi: Revenue Shares, by Country/Region, FY 2024

BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。

ライセンス別価格表

2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

新価格表

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

旧価格表

旧ライセンスタイプ1

旧ライセンスタイプ2

ご購入に関するご案内

価格・納期について

• 価格
• ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • 2-5ライセンス
    • 同一企業内5名までレポートファイルのご利用が可能です。
  • サイトライセンス
    • 同一企業同住所内でレポートファイルのご利用が可能です。
  • エンタープライズライセンス
    • 同一企業内人数無制限でレポートファイルのご利用が可能です。
• 納品形態
  • Eメール
• 納期
  • ご注文後3営業日以内

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 食品小売業およびEコマースにおけるAIの世界市場 2025-11-14
• 免疫療法薬の世界市場 2025-11-12
• 農業におけるAIの世界市場 2025-11-10
• 世界の電気アーク炉市場 2025-11-07
• 固体酸化物形燃料電池の技術と世界市場 2025-11-07

BCC Research  出版レポート一覧